Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration
Open accessThe DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index; 51 of the 251 sources its claims cite were checked for support.
Abstract
The diagnosis of neurodegenerative disorders is often challenging due to the lack of diagnostic tools, comorbidities and shared pathological manifestations. Synaptic dysfunction is an early pathological event in many neurodegenerative disorders, but the underpinning mechanisms are still poorly characterised. Reliable quantification of synaptic damage is crucial to understand the pathophysiology of neurodegeneration, to track disease status and to obtain prognostic information. Neuronal pentraxins (NPTXs) are extracellular scaffolding proteins emerging as potential biomarkers of synaptic dysfunction in neurodegeneration. They are a family of proteins involved in homeostatic synaptic plasticity by recruiting post-synaptic receptors into synapses. Recent research investigates the dynamic changes of NPTXs in the cerebrospinal fluid (CSF) as an expression of synaptic damage, possibly related to cognitive impairment. In this review, we summarise the available data on NPTXs structure and expression patterns as well as on their contribution in synaptic function and plasticity and other less well-characterised roles. Moreover, we propose a mechanism for their involvement in synaptic damage and neurodegeneration and assess their potential as CSF biomarkers for neurodegenerative diseases.
Overview
CoChat Summary
TL;DR
This review summarizes neuronal pentraxins (NPTX1, NPTX2, NPTXR) as synaptic organizer proteins and candidate CSF biomarkers of synaptic dysfunction in neurodegeneration. It proposes that NPTX changes may track early synaptic damage and cognitive decline, but current evidence is heterogeneous and mostly limited to CSF.
Key findings
- NPTXs are extracellular scaffolding proteins in the synaptic cleft; NPTX1 and NPTX2 form heteromultimers, bind NPTXR, and cluster/stabilize AMPAR at excitatory synapses onto parvalbumin interneurons. NPTX1 and NPTX2 show opposite activity-dependent regulation: NPTX1 is linked to low activity, apoptosis, and complement-mediated pruning, whereas NPTX2 is activity/BDNF-dependent and promotes plasticity. NPTXR knockout mice had 50% reduced brain NPTX1 and NPTX2 levels.
- In AD CSF, NPTX2 is decreased in MCI and AD versus controls; NPTX2 ratio with tau or p-tau showed the best performance to discriminate AD from controls, and NPTX2 predicted progression and correlated with cognition, medial temporal atrophy, and hippocampal volume. NPTX1 and NPTXR showed a biphasic pattern—elevated in MCI/early stages and decreased in dementia—with NPTXR declining by about 6.9%/year, 6.7%/year, or 10%/year in AD; NPTXR discriminated advanced AD from MCI with AUC = 0.799.
- In genetic and sporadic FTLD, NPTX1, NPTX2, and NPTXR were decreased in symptomatic mutation carriers versus pre-symptomatic carriers/non-carriers; NPTX2 had AUC = 0.71, comparable to neurogranin, and declined over time in symptomatic and pre-symptomatic carriers over age 50. In DLB, CSF NPTX2 was lower than in controls and correlated with visuospatial cognition; NPTX2 was highly upregulated in PD substantia nigra and accumulated in Lewy bodies.
- Proposed pathological mechanisms include astrocyte dysfunction and reduced BDNF lowering NPTX1/NPTX2 release, low neuronal activity driving NPTX1 mitochondrial BAX-dependent apoptosis, impaired TACE/NPTXR cleavage contributing to excitotoxicity, and intensified complement-microglia synaptic pruning.
Methods
- Narrative review of published literature on NPTX structure, expression patterns, physiological synaptic roles, and proposed involvement in synaptic damage and neurodegeneration.
- Summarizes CSF biomarker studies in AD and FTLD in Table 2, plus studies in synucleinopathies, psychiatric disorders, epilepsy, stroke, neuroinflammatory diseases, and brain tumors; cited measurement methods include mass spectrometry, ELISA, Western blot, and antibody suspension bead array.
- No primary cohort or meta-analysis is reported; the paper synthesizes existing studies and proposes mechanistic models.
Limitations
- Stated: reliable NPTX measurements can currently only be performed in CSF due to insufficient assay sensitivity in blood; lumbar puncture is invasive, so longitudinal studies are missing; lack of consistency between studies may result from different inclusion/exclusion criteria and absence of standardized analytical methods; prospective studies are required.
- Stated: observed NPTX alterations reflect a general pathological pattern rather than a disease-specific mechanism, and their suitability for clinical diagnostic purposes requires further investigation.
- Evident: this is a narrative rather than systematic review, and many cited studies are small, cross-sectional, and use heterogeneous assays, which the authors note may explain contradictory NPTX1/NPTXR findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
34 Valid · 1 Not valid · 129 Not checked · 26 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Finally, CSF levels of the different NPTXs strongly correlated with each other in both AD and genetic FTLD, indicating an overall reduction of these proteins in CSF (Nilsson et al. 2021; van der Ende et al. 2020; Xiao et al. 2017).”
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Neuronal pentraxins in synaptic dysfunction and neurodegeneration: a proposed mechanism > Neuronal pentraxins in neurodegenerative, psychiatric and other disorders of the CNS
What the sources say
- Disputedcites Nilsson et al. 2021 sourceExperimental — accuracy not yet measured
In Results > Clinical cohort (page unavailable), the paper says the pentraxins were exceptions to the generally strong correlations among panel proteins in AD samples. The Discussion (page unavailable) reports only a small decrease in AD for some pentraxins and none for neuronal pentraxin-1. This paper does not report a genetic FTLD cohort. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Supportedcites van der Ende et al. 2020 source
The Discussion reports that CSF NPTX1 and NPTXR correlated strongly with NPTX2 in genetic FTD and that these findings indicate an overall reduction in NPTXs. This source supports the genetic FTLD part of the multiply cited sentence; its Discussion mentions AD findings but does not report correlations among NPTXs in AD. (LLM, conf=0.90)
- Partly supportedcites Xiao et al. 2017 sourceExperimental — accuracy not yet measured
In Results, ‘CSF NPTX2 provides a biomarker of brain NPTX2’ (Figure 5; page not provided), the paper says CSF NPTX1 and NPTXR strongly correlate with NPTX2 in individual samples and that all three are reduced in AD CSF. It does not report findings for genetic FTLD, so it supports the AD portion but not the claim as applied to both conditions. (LLM, conf=0.90)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“NPTXs might be a selective marker for the imbalance of pyramidal neuron-interneuron microcircuits, thought to underlie cognitive impairment in AD (Xiao et al. 2017).”
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Introduction
What the sources say
- Supportedcites Xiao et al. 2017 source
The Results section (‘CSF NPTX2 provides a biomarker of brain NPTX2’; page unavailable) reports reduced CSF levels of NPTX1, NPTX2, and NPTXR in AD and infers that the PV-interneuron circuit is their major CSF source. The Discussion (page unavailable) proposes that NPTX2 down-regulation contributes to pyramidal neuron–PV interneuron circuit dysfunction and cognitive failure in AD. The citing sentence appropriately hedges this as a possible marker and proposed mechanism. (LLM, conf=0.90)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“NPTXs play a role in synaptogenesis (Farhy-Tselnicker et al. 2017; Figueiro-Silva et al. 2015; Sia et al. 2007)”
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Neuronal pentraxins: a subfamily of highly conserved pentraxins > Role of neuronal pentraxins in synaptic function and plasticity
What the sources say
- Supportedcites Farhy-Tselnicker et al. 2017 source
The Results section, “Interaction between NP1 and GluA1 Is Necessary for Glypican 4 to Induce Synapse Formation” (page not provided), reports that knocking down neuronal pentraxin 1 (NP1) prevented Gpc4-induced synapse formation. The Introduction (page not provided) also states that removing neuronal pentraxins delays active synapse formation in developing neurons. (LLM, conf=0.94)
- Supportedcites Figueiro-Silva et al. 2015 source
The Discussion states that NP1 limits excitatory synaptogenesis and restricts synapse formation. This directly supports the claim that neuronal pentraxins play a role in synaptogenesis. (LLM, conf=0.94)
- Not checked yetcites Sia et al. 2007 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“BNDF-induced NPTX2 is required for glutamatergic synaptic transmission and LTP in mossy fibres in the dendate gyrus (Mariga et al. 2015; Wibrand et al. 2006).”
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Neuronal pentraxins: a subfamily of highly conserved pentraxins > Role of neuronal pentraxins in synaptic function and plasticity
What the sources say
- Partly supportedcites Mariga et al. 2015 sourceExperimental — accuracy not yet measured
The Results section (‘Narp is important for BDNF-dependent synaptic function’; page unavailable) reports impaired mossy-fiber LTP in Narp-deficient mice and finds that BDNF-mediated enhancement of glutamate release depends on Narp. It does not establish that Narp is required for glutamatergic transmission generally, rather than its enhancement by BDNF. The experiments concern the mossy fiber–CA3 pathway, not synapses within the dentate gyrus. (LLM, conf=0.85)
- Not checked yetcites Wibrand et al. 2006 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Under physiological conditions, NPTX2 is mainly secreted from the pre-synaptic terminal into the synapses (Chang et al. 2010; Reti et al. 2002).”
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Neuronal pentraxins: a subfamily of highly conserved pentraxins > Role of neuronal pentraxins in synaptic function and plasticity
What the sources say
- Partly supportedcites Chang et al. 2010 sourceExperimental — accuracy not yet measured
The Introduction identifies Narp as neuronal pentraxin 2 (NPTX2) and says it is secreted from presynaptic excitatory neurons and accumulates at synapses on parvalbumin-expressing interneurons. The Results section, “Narp at PV-IN synapses derives from presynaptic neurons,” says it originates primarily from presynaptic neurons. The paper does not establish that NPTX2 is mainly secreted from presynaptic terminals into synapses generally under physiological conditions. (LLM, conf=0.86)
- Not checked yetcites Reti et al. 2002 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
116 more claims · 24 with their cited sources checked
Create a free account to see all 190 claims and to verify the 200 references still open.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 22
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The downregulation of NPTX2 in both genetic and sporadic bvFTD may thus reflect a shared pathophysiology within the FTD disease heterogeneity and suggest that NPTX2 may play a crucial role in the pathogenesis of FTD by contributing to synaptic dysfunction [42].”
From The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The downregulation of NPTX2 in both genetic and sporadic bvFTD may thus reflect a shared pathophysiology within the FTD disease heterogeneity and suggest that NPTX2 may play a crucial role in the pathogenesis of FTD by contributing to synaptic dysfunction [42].”
From The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredIn the citing paper
“NPTX2 is involved in the formation and stabilization of synapses, facilitating proper communication between neurons in the brain, and plays a crucial role in synaptic function and plasticity [42].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Introduction
“Given that lumbar puncture is an invasive procedure, longitudinal studies are missing.”
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Neuronal pentraxins in synaptic dysfunction and neurodegeneration: a proposed mechanism > Neuronal pentraxins in neurodegenerative, psychiatric and other disorders of the CNS
“A preliminary longitudinal analysis of 13 patients revealed a decline over time in NPTX2 in symptomatic mutation carriers and in pre-symptomatic mutations carriers over the age of 50 years (van der Ende et al. 2020).”
Citations
Cites
1 retracted
RETRACTED: NPTX1 Regulates Neural Lineage Specification from Human Pluripotent Stem Cells
Boles, N. C., Hirsch, S. E., Le, S., Corneo, B., Najm, F., Minotti, A. P., Wang, Q., Lotz, S., Tesar, P. J., & Fasano, C. A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.026 · Cited by 64
RetractedHighly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
SWISS-MODEL: homology modelling of protein structures and complexes
Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., de Beer, T. A. P., Rempfer, C., Bordoli, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky427 · Cited by 13,067
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
UniProt: the universal protein knowledgebase in 2021
The UniProt Consortium, Bateman, A., Martin, M.-J., Orchard, S., Magrane, M., Agivetova, R., Ahmad, S., Alpi, E., Bowler-Barnett, E. H., Britto, R., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1100 · Cited by 6,372 · cited 1×
“2013; Tseng and Bixby 2011).”
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Improved protein structure prediction using potentials from deep learning
Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A., Nelson, A. W. R., Bridgland, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1923-7 · Cited by 3,378
An anatomically comprehensive atlas of the adult human brain transcriptome
Hawrylycz, M. J., Lein, E. S., Guillozet-Bongaarts, A. L., Shen, E. H., Ng, L., Miller, J. A., van de Lagemaat, L. N., Smith, K. A., Ebbert, A., Riley, Z. L., et al. (2012) · Nature · doi:10.1038/nature11405 · Cited by 3,083
Appelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Driving fast-spiking cells induces gamma rhythm and controls sensory responses
Cardin, J. A., Carlén, M., Meletis, K., Knoblich, U., Zhang, F., Deisseroth, K., Tsai, L.-H., & Moore, C. I. (2009) · Nature · doi:10.1038/nature08002 · Cited by 2,603
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Region of interest analysis using an SPM toolbox
Brett, M. (2002) · NeuroImage · Cited by 2,273
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644
Gamma frequency entrainment attenuates amyloid load and modifies microglia
Iaccarino, H. F., Singer, A. C., Martorell, A. J., Rudenko, A., Gao, F., Gillingham, T. Z., Mathys, H., Seo, J., Kritskiy, O., Abdurrob, F., et al. (2016) · Nature · doi:10.1038/nature20587 · Cited by 1,328
Dong, X.-X., Wang, Y., & Qin, Z.-H. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.24 · Cited by 1,297
Verret, L., Mann, E. O., Hang, G. B., Barth, A. M. I., Cobos, I., Ho, K., Devidze, N., Masliah, E., Kreitzer, A. C., Mody, I., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.046 · Cited by 1,216
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207
Fast-spiking, parvalbumin + GABAergic interneurons: From cellular design to microcircuit function
Hu, H., Gan, J., & Jonas, P. (2014) · Science · doi:10.1126/science.1255263 · Cited by 1,197
Bang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144
Network abnormalities and interneuron dysfunction in Alzheimer disease
Palop, J. J., & Mucke, L. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.141 · Cited by 1,022
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders
Nelson, S. B., & Valakh, V. (2015) · Neuron · doi:10.1016/j.neuron.2015.07.033 · Cited by 1,001
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD
Dickerson, B. C., Salat, D. H., Greve, D. N., Chua, E. F., Rand-Giovannetti, E., Rentz, D. M., Bertram, L., Mullin, K., Tanzi, R. E., Blacker, D., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000171450.97464.49 · Cited by 910
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Hippocampal GABAergic Inhibitory Interneurons
Pelkey, K. A., Chittajallu, R., Craig, M. T., Tricoire, L., Wester, J. C., & McBain, C. J. (2017) · Physiological Reviews · doi:10.1152/physrev.00007.2017 · Cited by 889
Garlanda, C., Bottazzi, B., Bastone, A., & Mantovani, A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115756 · Cited by 836
Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., DeKosky, S. T., & Mufson, E. J. (2007) · Neurology · doi:10.1212/01.wnl.0000260698.46517.8f · Cited by 824
Arc/Arg3.1 Mediates Homeostatic Synaptic Scaling of AMPA Receptors
Shepherd, J. D., Rumbaugh, G., Wu, J., Chowdhury, S., Plath, N., Kuhl, D., Huganir, R. L., & Worley, P. F. (2006) · Neuron · doi:10.1016/j.neuron.2006.08.034 · Cited by 779
Gamma Oscillations Correlate with Working Memory Load in Humans
Howard, M. W. (2003) · Cerebral Cortex · doi:10.1093/cercor/bhg084 · Cited by 766
Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes
Belforte, J. E., Zsiros, V., Sklar, E. R., Jiang, Z., Yu, G., Li, Y., Quinlan, E. M., & Nakazawa, K. (2010) · Nature Neuroscience · doi:10.1038/nn.2447 · Cited by 752
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750
Lui, H., Zhang, J., Makinson, S. R., Cahill, M. K., Kelley, K. W., Huang, H.-Y., Shang, Y., Oldham, M. C., Martens, L. H., Gao, F., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.001 · Cited by 729
Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease
Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720
Towards an Understanding of Synapse Formation
Südhof, T. C. (2018) · Neuron · doi:10.1016/j.neuron.2018.09.040 · Cited by 698 · cited 1×
“Synaptic transmission is fundamental to neural functions, including memory formation and learning (Südhof 2018).”
BackgroundSchizophrenia as a Disorder of Developmentally Reduced Synaptic Connectivity
McGlashan, T. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.7.637 · Cited by 655
Davies, C. A., Mann, D. M. A., Sumpter, P. Q., & Yates, P. O. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90057-8 · Cited by 628
Ferguson, B. R., & Gao, W.-J. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00037 · Cited by 594
An Integrated View of Humoral Innate Immunity: Pentraxins as a Paradigm
Bottazzi, B., Doni, A., Garlanda, C., & Mantovani, A. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101305 · Cited by 592
Hypocretin (orexin) cell loss in Parkinson's disease
Thannickal, T. C., Lai, Y.-Y., & Siegel, J. M. (2007) · Brain · doi:10.1093/brain/awm097 · Cited by 566
Fuchs, E. C., Zivkovic, A. R., Cunningham, M. O., Middleton, S., LeBeau, F. E. N., Bannerman, D. M., Rozov, A., Whittington, M. A., Traub, R. D., Rawlins, J. N. P., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.031 · Cited by 532
Gao, R., & Penzes, P. (2015) · Current Molecular Medicine · doi:10.2174/1566524015666150303003028 · Cited by 516
Korotkova, T., Fuchs, E. C., Ponomarenko, A., von Engelhardt, J., & Monyer, H. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.017 · Cited by 480
Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product narp.
O’Brien, R. J., Xu, D., Petralia, R. S., Steward, O., Huganir, R. L., & Worley, P. (1999) · Neuron · doi:10.1016/s0896-6273(00)80782-5 · Cited by 471
Structure of pentameric human serum amyloid P component
Emsley, J., White, H. E., O'Hara, B. P., Oliva, G., Srinivasan, N., Tickle, I. J., Blundell, T. L., Pepys, M. B., & Wood, S. P. (1994) · Nature · doi:10.1038/367338a0 · Cited by 464
Astrocytes in Neurodegenerative Disease: Table 1.
Phatnani, H., & Maniatis, T. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020628 · Cited by 420
Breviario, F., d'Aniello, E. M., Golay, J., Peri, G., Bottazzi, B., Bairoch, A., Saccone, S., Marzella, R., Predazzi, V, & Rocchi, M. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41653-5 · Cited by 417
Synaptopathies: synaptic dysfunction in neurological disorders – A review from students to students
Lepeta, K., Lourenco, M. V., Schweitzer, B. C., Martino Adami, P. V., Banerjee, P., Catuara‐Solarz, S., de La Fuente Revenga, M., Guillem, A. M., Haidar, M., Ijomone, O. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13713 · Cited by 386
Dementia with Lewy bodies: an update and outlook
Outeiro, T. F., Koss, D. J., Erskine, D., Walker, L., Kurzawa-Akanbi, M., Burn, D., Donaghy, P., Morris, C., Taylor, J.-P., Thomas, A., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0306-8 · Cited by 381
Differential loss of synaptic proteins in Alzheimer's disease: Implications for synaptic dysfunction
Reddy, P. H., Mani, G., Park, B. S., Jacques, J., Murdoch, G., Whetsell, W., Kaye, J., & Manczak, M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7203 · Cited by 372
Three dimensional structure of human C-reactive protein
Shrive, A. K., Gheetham, G. M. T., Holden, D., Myles, D. A. A., Turnell, W. G., Volanakis, J. E., Pepys, M. B., Bloomer, A. C., & Greenhough, T. J. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0496-346 · Cited by 356
Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis
Henstridge, C. M., Hyman, B. T., & Spires-Jones, T. L. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0113-1 · Cited by 348
Tumor necrosis factor-α converting enzyme
Black, R. A. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00097-8 · Cited by 346
Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model
Janezic, S., Threlfell, S., Dodson, P. D., Dowie, M. J., Taylor, T. N., Potgieter, D., Parkkinen, L., Senior, S. L., Anwar, S., Ryan, B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309143110 · Cited by 344
Immediate Early Genes, Memory and Psychiatric Disorders: Focus on c-Fos, Egr1 and Arc
Gallo, F. T., Katche, C., Morici, J. F., Medina, J. H., & Weisstaub, N. V. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00079 · Cited by 344
Härtig, W., Derouiche, A., Welt, K., Brauer, K., Grosche, J., Mäder, M., Reichenbach, A., & Brückner, G. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01784-9 · Cited by 339
Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson’s Disease
Nguyen, M., Wong, Y. C., Ysselstein, D., Severino, A., & Krainc, D. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.11.001 · Cited by 323
Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons
Chang, M. C., Park, J. M., Pelkey, K. A., Grabenstatter, H. L., Xu, D., Linden, D. J., Sutula, T. P., McBain, C. J., & Worley, P. F. (2010) · Nature Neuroscience · doi:10.1038/nn.2621 · Cited by 316
NPTX2 and cognitive dysfunction in Alzheimer’s Disease
Xiao, M.-F., Xu, D., Craig, M. T., Pelkey, K. A., Chien, C.-C., Shi, Y., Zhang, J., Resnick, S., Pletnikova, O., Salmon, D., et al. (2017) · eLife · doi:10.7554/elife.23798 · Cited by 316
Tsui, C., Copeland, N., Gilbert, D., Jenkins, N., Barnes, C., & Worley, P. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-08-02463.1996 · Cited by 315
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
McDade, E., Wang, G., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Holtzman, D. M., Cairns, N. J., Goate, A. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006277 · Cited by 314
Foss-Feig, J. H., Adkinson, B. D., Ji, J. L., Yang, G., Srihari, V. H., McPartland, J. C., Krystal, J. H., Murray, J. D., & Anticevic, A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.005 · Cited by 310
Concomitant loss of dynorphin, NARP, and orexin in narcolepsy
Crocker, A., España, R. A., Papadopoulou, M., Saper, C. B., Faraco, J., Sakurai, T., Honda, M., Mignot, E., & Scammell, T. E. (2005) · Neurology · doi:10.1212/01.wnl.0000168173.71940.ab · Cited by 301
Fundamental Elements in Autism: From Neurogenesis and Neurite Growth to Synaptic Plasticity
Gilbert, J., & Man, H.-Y. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00359 · Cited by 280
Neuroinflammation in frontotemporal dementia
Bright, F., Werry, E. L., Dobson-Stone, C., Piguet, O., Ittner, L. M., Halliday, G. M., Hodges, J. R., Kiernan, M. C., Loy, C. T., Kassiou, M., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0231-z · Cited by 280
Homeostatic Scaling Requires Group I mGluR Activation Mediated by Homer1a
Hu, J.-H., Park, J. M., Park, S., Xiao, B., Dehoff, M. H., Kim, S., Hayashi, T., Schwarz, M. K., Huganir, R. L., Seeburg, P. H., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.008 · Cited by 266
Xu, D., Hopf, C., Reddy, R., Cho, R. W., Guo, L., Lanahan, A., Petralia, R. S., Wenthold, R. J., O'Brien, R. J., & Worley, P. (2003) · Neuron · doi:10.1016/s0896-6273(03)00463-x · Cited by 265
Neurobiological bases of autism–epilepsy comorbidity: a focus on excitation/inhibition imbalance
Bozzi, Y., Provenzano, G., & Casarosa, S. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.13595 · Cited by 250
L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma
Norman, M., Ter-Ovanesyan, D., Trieu, W., Lazarovits, R., Kowal, E. J. K., Lee, J. H., Chen-Plotkin, A. S., Regev, A., Church, G. M., & Walt, D. R. (2021) · Nature Methods · doi:10.1038/s41592-021-01174-8 · Cited by 250
Pelkey, K. A., Barksdale, E., Craig, M. T., Yuan, X., Sukumaran, M., Vargish, G. A., Mitchell, R. M., Wyeth, M. S., Petralia, R. S., Chittajallu, R., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.020 · Cited by 245
Lee, G. W., Lee, T. H., & Vilcek, J. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.5.1804 · Cited by 245
Increased CSF neurogranin concentration is specific to Alzheimer disease
Wellington, H., Paterson, R. W., Portelius, E., Törnqvist, U., Magdalinou, N., Fox, N. C., Blennow, K., Schott, J. M., & Zetterberg, H. (2016) · Neurology · doi:10.1212/wnl.0000000000002423 · Cited by 232
Schmidt, T., Samaras, P., Frejno, M., Gessulat, S., Barnert, M., Kienegger, H., Krcmar, H., Schlegl, J., Ehrlich, H.-C., Aiche, S., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1029 · Cited by 221
Lleó, A., Núñez-Llaves, R., Alcolea, D., Chiva, C., Balateu-Paños, D., Colom-Cadena, M., Gomez-Giro, G., Muñoz, L., Querol-Vilaseca, M., Pegueroles, J., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001290 · Cited by 219
Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., & Schwartz, J. B. (2018) · The FASEB Journal · doi:10.1096/fj.201700731r · Cited by 219
GABAergic Inhibitory Interneuron Deficits in Alzheimer’s Disease: Implications for Treatment
Xu, Y., Zhao, M., Han, Y., & Zhang, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00660 · Cited by 203
Sia, G.-M., Béïque, J.-C., Rumbaugh, G., Cho, R., Worley, P. F., & Huganir, R. L. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.020 · Cited by 201
Farhy-Tselnicker, I., van Casteren, A. C. M., Lee, A., Chang, V. T., Aricescu, A. R., & Allen, N. J. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.053 · Cited by 199
Parvalbumin interneuron vulnerability and brain disorders
Ruden, J. B., Dugan, L. L., & Konradi, C. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-0778-9 · Cited by 194
Gascon, E., Lynch, K., Ruan, H., Almeida, S., Verheyden, J. M., Seeley, W. W., Dickson, D. W., Petrucelli, L., Sun, D., Jiao, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3717 · Cited by 183
Neuronal Pentraxins Mediate Synaptic Refinement in the Developing Visual System
Bjartmar, L., Huberman, A. D., Ullian, E. M., Renteria, R. C., Liu, X., Xu, W., Prezioso, J., Susman, M. W., Stellwagen, D., Stokes, C. C., et al. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.4212-05.2006 · Cited by 179
Dodds, D. C., Omeis, I. A., Cushman, S. J., Helms, J. A., & Perin, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21488 · Cited by 170
Fluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165
Neuronal pentraxin, a secreted protein with homology to acute phase proteins of the immune system
Schlimgen, A. K., Helms, J. A., Vogel, H., & Perin, M. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90308-9 · Cited by 163
Spellman, D. S., Wildsmith, K. R., Honigberg, L. A., Tuefferd, M., Baker, D., Raghavan, N., Nairn, A. C., Croteau, P., Schirm, M., Allard, R., et al. (2015) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201400178 · Cited by 161
O'Brien, R., Xu, D., Mi, R., Tang, X., Hopf, C., & Worley, P. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-11-04487.2002 · Cited by 160
Wibrand, K., Messaoudi, E., Håvik, B., Steenslid, V., Løvlie, R., Steen, V. M., & Bramham, C. R. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04687.x · Cited by 153
Berretta, S., Pantazopoulos, H., Markota, M., Brown, C., & Batzianouli, E. T. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.040 · Cited by 152
Biochemical Interactions of the Neuronal Pentraxins
Kirkpatrick, L., Matzuk, M. M., Dodds, D. C., & Perin, M. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002254200 · Cited by 149
Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses
Lee, S.-J., Wei, M., Zhang, C., Maxeiner, S., Pak, C., Calado Botelho, S., Trotter, J., Sterky, F. H., & Südhof, T. C. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2768-16.2016 · Cited by 146
Yin, G. N., Lee, H. W., Cho, J.-Y., & Suk, K. (2009) · Brain Research · doi:10.1016/j.brainres.2009.01.058 · Cited by 143
Wildsmith, K. R., Schauer, S. P., Smith, A. M., Arnott, D., Zhu, Y., Haznedar, J., Kaur, S., Mathews, W., & Honigberg, L. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-22 · Cited by 140
Findley, C. A., Bartke, A., Hascup, K. N., & Hascup, E. R. (2019) · ASN NEURO · doi:10.1177/1759091419855541 · Cited by 139
Bonansco, C., & Fuenzalida, M. (2016) · Neural Plasticity · doi:10.1155/2016/8607038 · Cited by 138
Duits, F. H., Brinkmalm, G., Teunissen, C. E., Brinkmalm, A., Scheltens, P., Van der Flier, W. M., Zetterberg, H., & Blennow, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0335-x · Cited by 137
Kvartsberg, H., Portelius, E., Andreasson, U., Brinkmalm, G., Hellwig, K., Lelental, N., Kornhuber, J., Hansson, O., Minthon, L., Spitzer, P., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0124-3 · Cited by 136
A synthetic synaptic organizer protein restores glutamatergic neuronal circuits
Suzuki, K., Elegheert, J., Song, I., Sasakura, H., Senkov, O., Matsuda, K., Kakegawa, W., Clayton, A. J., Chang, V. T.-C., Ferrer-Ferrer, M., et al. (2020) · Science · doi:10.1126/science.abb4853 · Cited by 134
Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.002 · Cited by 133
Synaptic dysfunction and septin protein family members in neurodegenerative diseases
Marttinen, M., Kurkinen, K. M., Soininen, H., Haapasalo, A., & Hiltunen, M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0013-z · Cited by 130
Asymptomatic Alzheimers Disease: A Prodrome or a State of Resilience?
Driscoll, I., & Troncoso, J. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745348 · Cited by 130
Levenga, J., Krishnamurthy, P., Rajamohamedsait, H., Wong, H., Franke, T. F., Cain, P., Sigurdsson, E. M., & Hoeffer, C. A. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-34 · Cited by 130
Cho, R. W., Park, J. M., Wolff, S. B. E., Xu, D., Hopf, C., Kim, J.-A., Reddy, R. C., Petralia, R. S., Perin, M. S., Linden, D. J., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.010 · Cited by 125
Parvalbumin-immunoreactive neurons in the hippocampal formation of Alzheimer’s diseased brain
Brady, D. R., & Mufson, E. J. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00068-7 · Cited by 125
Two Classes of Secreted Synaptic Organizers in the Central Nervous System
Yuzaki, M. (2018) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021317-121322 · Cited by 125
Neurochemical Features of Frontotemporal Dementia
Procter, A. W., Qurne, M., & Francis, P. T. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051219 · Cited by 124
Ringman, J. M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.642 · Cited by 124
Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer’s disease
Takahashi, H., Brasnjevic, I., Rutten, B. P. F., Van Der Kolk, N., Perl, D. P., Bouras, C., Steinbusch, H. W. M., Schmitz, C., Hof, P. R., & Dickstein, D. L. (2010) · Brain Structure and Function · doi:10.1007/s00429-010-0242-4 · Cited by 124
Eastwood, S. L., & Harrison, P. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.12.004 · Cited by 122
New tricks for an ancient system: Physiological and pathological roles of complement in the CNS
Tenner, A. J., Stevens, B., & Woodruff, T. M. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.06.264 · Cited by 122
Fluid biomarkers in frontotemporal dementia: past, present and future
Swift, I. J., Sogorb-Esteve, A., Heller, C., Synofzik, M., Otto, M., Graff, C., Galimberti, D., Todd, E., Heslegrave, A. J., van der Ende, E. L., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323520 · Cited by 122
Self-citationObligatory Role for the Immediate Early Gene NARP in Critical Period Plasticity
Gu, Y., Huang, S., Chang, M. C., Worley, P., Kirkwood, A., & Quinlan, E. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.05.016 · Cited by 116
Carceller, H., Guirado, R., Ripolles-Campos, E., Teruel-Marti, V., & Nacher, J. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0291-20.2020 · Cited by 112
Loss of perineuronal net N-acetylgalactosamine in Alzheimer’s disease
Baig, S., Wilcock, G. K., & Love, S. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1060-2 · Cited by 112
GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition
Murley, A. G., Rouse, M. A., Jones, P. S., Ye, R., Hezemans, F. H., O’Callaghan, C., Frangou, P., Kourtzi, Z., Rua, C., Carpenter, T. A., et al. (2020) · Brain · doi:10.1093/brain/awaa305 · Cited by 112
Isolation of Human C-Reactive Protein Complementary DNA and Localization of the Gene to Chromosome 1
Whitehead, A. S., Bruns, G. A. P., Markham, A. F., Colten, H. R., & Woods, D. E. (1983) · Science · doi:10.1126/science.6857266 · Cited by 111
Brinkmalm, G., Sjödin, S., Simonsen, A. H., Hasselbalch, S. G., Zetterberg, H., Brinkmalm, A., & Blennow, K. (2018) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201700131 · Cited by 111
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
Libiger, O., Shaw, L. M., Watson, M. H., Nairn, A. C., Umaña, K. L., Biarnes, M. C., Canet‐Avilés, R. M., Jack, C. R., Breton, Y., Cortes, L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12353 · Cited by 108
Neuroimmune regulation of homeostatic synaptic plasticity
Pribiag, H., & Stellwagen, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.008 · Cited by 106
Brain Derived Exosomes Are a Double-Edged Sword in Alzheimer’s Disease
Song, Z., Xu, Y., Deng, W., Zhang, L., Zhu, H., Yü, P., Qu, Y., Zhao, W., Han, Y., & Qin, C. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00079 · Cited by 106
Human Neuronal Pentraxin II (NPTX2): Conservation, Genomic Structure, and Chromosomal Localization
Hsu, Y., & Perin, M. S. (1995) · Genomics · doi:10.1006/geno.1995.1134 · Cited by 104
Abad, M. A., Enguita, M., DeGregorio-Rocasolano, N., Ferrer, I., & Trullas, R. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0575-06.2006 · Cited by 102
Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
van der Ende, E. L., Xiao, M., Xu, D., Poos, J. M., Panman, J. L., Jiskoot, L. C., Meeter, L. H., Dopper, E. G., Papma, J. M., Heller, C., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322493 · Cited by 94
Self-citationTargeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer’s Disease
Oeckl, P., Halbgebauer, S., Anderl-Straub, S., von Arnim, C. A. F., Diehl-Schmid, J., Froelich, L., Grimmer, T., Hausner, L., Denk, J., Jahn, H., et al. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00824 · Cited by 91
Self-citationKhundakar, A. A., Hanson, P. S., Erskine, D., Lax, N. Z., Roscamp, J., Karyka, E., Tsefou, E., Singh, P., Cockell, S., Gribben, A., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0334-3 · Cited by 90
Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
Nilsson, J., Gobom, J., Sjödin, S., Brinkmalm, G., Ashton, N. J., Svensson, J., Johansson, P., Portelius, E., Zetterberg, H., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12179 · Cited by 82
Synaptic Paths to Neurodegeneration: The Emerging Role of TDP-43 and FUS in Synaptic Functions
Ling, S.-C. (2018) · Neural Plasticity · doi:10.1155/2018/8413496 · Cited by 81
Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls
Kroksveen, A. C., Guldbrandsen, A., Vedeler, C., Myhr, K. M., Opsahl, J. A., & Berven, F. S. (2012) · Acta Neurologica Scandinavica · doi:10.1111/ane.12029 · Cited by 80
Swanson, A., & Willette, A. A. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.148 · Cited by 79
Lopes, M. W., Soares, F. M. S., de Mello, N., Nunes, J. C., Cajado, A. G., de Brito, D., de Cordova, F. M., da Cunha, R. M. S., Walz, R., & Leal, R. B. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3421-8 · Cited by 78
Gong, Y., & Lippa, C. F. (2010) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317510382893 · Cited by 76
Evolution of the Pentraxin Family: The New Entry PTX4
Martinez de la Torre, Y., Fabbri, M., Jaillon, S., Bastone, A., Nebuloni, M., Vecchi, A., Mantovani, A., & Garlanda, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901672 · Cited by 75
The Basic Characteristics of the Pentraxin Family and Their Functions in Tumor Progression
Wang, Z., Wang, X., Zou, H., Dai, Z., Feng, S., Zhang, M., Xiao, G., Liu, Z., & Cheng, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01757 · Cited by 73
Neuroinflammation in Alzheimer’s disease: Pleiotropic roles for cytokines and neuronal pentraxins
Swanson, A., Wolf, T., Sitzmann, A., & Willette, A. A. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.02.015 · Cited by 72
Synaptic proteins in CSF relate to Parkinson’s disease stage markers
Bereczki, E., Bogstedt, A., Höglund, K., Tsitsi, P., Brodin, L., Ballard, C., Svenningsson, P., & Aarsland, D. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0008-2 · Cited by 72
Hendrickson, R. C., Lee, A. Y. H., Song, Q., Liaw, A. I., Wiener, M., Paweletz, C. P., Seeburger, J. L., Li, J., Meng, F., Deyanova, E. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135365 · Cited by 69
Moran, L. B., Hickey, L., Michael, G. J., Derkacs, M., Christian, L. M., Kalaitzakis, M. E., Pearce, R. K. B., & Graeber, M. B. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0309-3 · Cited by 69
Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer’s disease
Halbgebauer, S., Oeckl, P., Steinacker, P., Yilmazer‐Hanke, D., Anderl‐Straub, S., Arnim, C. A. F. V., Froelich, L., Gomes, L. A., Hausner, L., Huss, A. M., et al. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-324306 · Cited by 66
Self-citationIdentification of differentially expressed genes induced by transient ischemic stroke
Schwarz, D. A., Barry, G., Mackay, K. B., Manu, F., Naeve, G. S., Vana, A. M., Verge, G., Conlon, P. J., Foster, A. C., & Maki, R. A. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00135-3 · Cited by 65
Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics
van der Ende, E. L., Meeter, L. H., Stingl, C., van Rooij, J. G. J., Stoop, M. P., Nijholt, D. A. T., Sanchez‐Valle, R., Graff, C., Öijerstedt, L., Grossman, M., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.745 · Cited by 65
Omeis, I. A., Hsu, Y.-C., & Perin, M. S. (1996) · Genomics · doi:10.1006/geno.1996.0503 · Cited by 63
Synaptic Proteins and Choline Acetyltransferase Loss in Visual Cortex in Dementia With Lewy Bodies
Mukaetova-Ladinska, E. B., Andras, A., Milne, J., Abdel-All, Z., Borr, I., Jaros, E., Perry, R. H., Honer, W. G., Cleghorn, A., Doherty, J., et al. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31827c5710 · Cited by 62
Rui, Y., Gu, J., Yu, K., Hartzell, H. C., & Zheng, J. Q. (2010) · Molecular Brain · doi:10.1186/1756-6606-3-10 · Cited by 61
Gene Expression Analyses Identify Narp Contribution in the Development of l-DOPA-Induced Dyskinesia
Charbonnier‐Beaupel, F., Malerbi, M., Alcacer, C., Tahiri, K., Carpentier, W., Wang, C., During, M. J., Xu, D., Worley, P. F., Girault, J., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.5231-13.2015 · Cited by 56
DeGregorio-Rocasolano, N., Gasull, T., & Trullas, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007967200 · Cited by 56
Remnestål, J., Öijerstedt, L., Ullgren, A., Olofsson, J., Bergström, S., Kultima, K., Ingelsson, M., Kilander, L., Uhlén, M., Månberg, A., et al. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00198-y · Cited by 56
Neuronal Pentraxin 1 Negatively Regulates Excitatory Synapse Density and Synaptic Plasticity
Figueiro-Silva, J., Gruart, A., Clayton, K. B., Podlesniy, P., Abad, M. A., Gasull, X., Delgado-García, J. M., & Trullas, R. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2548-14.2015 · Cited by 53
Huo, L., Wang, B., Zheng, M., Zhang, Y., Xu, J., Yang, G., & Guan, Q. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7284 · Cited by 53
Lang, Y., Li, Y., Yu, H., Lin, L., Chen, X., Wang, S., & Zhang, H. (2020) · Aging · doi:10.18632/aging.103028 · Cited by 52
Begcevic, I., Tsolaki, M., Brinc, D., Brown, M., Martinez-Morillo, E., Lazarou, I., Kozori, M., Tagaraki, F., Nenopoulou, S., Gkioka, M., et al. (2018) · F1000Research · doi:10.12688/f1000research.15095.1 · Cited by 51
Soldan, A., Moghekar, A., Walker, K. A., Pettigrew, C. A., Hou, X., Lu, H., Miller, M. I., Alfini, A. J., Albert, M., Xu, D., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00132 · Cited by 51
Llano, D. A., Bundela, S., Mudar, R. A., Devanarayan, V., & (ADNI), F. T. A. D. N. I. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182098 · Cited by 50
Magdalinou, N. K., Noyce, A. J., Pinto, R., Lindstrom, E., Holmén-Larsson, J., Holtta, M., Blennow, K., Morris, H. R., Skillbäck, T., Warner, T. T., et al. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.01.016 · Cited by 49
Maheshwari, A., Nahm, W. K., & Noebels, J. L. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00156 · Cited by 47
Definition of a Bidirectional Activity-Dependent Pathway Involving BDNF and Narp
Mariga, A., Glaser, J., Mathias, L., Xu, D., Xiao, M., Worley, P., Ninan, I., & Chao, M. V. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.064 · Cited by 45
Barschke, P., Oeckl, P., Steinacker, P., Al Shweiki, M. R., Weishaupt, J. H., Landwehrmeyer, G. B., Anderl-Straub, S., Weydt, P., Diehl-Schmid, J., Danek, A., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322476 · Cited by 45
Self-citationCummings, D. M., Benway, T. A., Ho, H., Tedoldi, A., Fernandes Freitas, M. M., Shahab, L., Murray, C. E., Richard-Loendt, A., Brandner, S., Lashley, T., et al. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx046 · Cited by 43
Kovács, R. Á., Vadászi, H., Bulyáki, É., Török, G., Tóth, V., Mátyás, D., Kun, J., Hunyadi-Gulyás, É., Fedor, F. Z., Csincsi, Á., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.599771 · Cited by 43
Prominent Narp expression in projection pathways and terminal fields
Reti, I. M., Reddy, R., Worley, P. F., & Baraban, J. M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01051.x · Cited by 42
Boiten, W., van Steenoven, I., Xiao, M.-F., Worley, P., Noli, B., Cocco, C., Ferri, G.-L., Lemstra, A., & Teunissen, C. (2020) · Cells · doi:10.3390/cells10010038 · Cited by 42
Lim, B., Sando, S. B., Grøntvedt, G. R., Bråthen, G., & Diamandis, E. P. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.013 · Cited by 39
Belbin, O., Xiao, M.-F., Xu, D., Carmona-Iragui, M., Pegueroles, J., Benejam, B., Videla, L., Fernández, S., Barroeta, I., Nuñez-Llaves, R., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00398-0 · Cited by 39
Critical role of neuronal pentraxin 1 in mitochondria-mediated hypoxic–ischemic neuronal injury
Al Rahim, M., Thatipamula, S., & Hossain, M. A. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.003 · Cited by 37
Caputi, A., Fuchs, E. C., Allen, K., Le Magueresse, C., & Monyer, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037318 · Cited by 34
Bartolini, A., Paolo, D. D., Noghero, A., Murgia, D., Sementa, A. R., Cilli, M., Pasqualini, R., Arap, W., Bussolino, F., Ponzoni, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0649 · Cited by 32
Radin, D. P., & Patel, P. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.024 · Cited by 32
Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease
Ma, Q.-L., Teng, E., Zuo, X., Jones, M., Teter, B., Zhao, E. Y., Zhu, C., Bilousova, T., Gylys, K. H., Apostolova, L. G., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.02.014 · Cited by 32
Tseng, L. A., & Bixby, J. L. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.04.005 · Cited by 28
Clayton, K. B., Podlesniy, P., Figueiro-Silva, J., López-Doménech, G., Benitez, L., Enguita, M., Abad, M. A., Soriano, E., & Trullas, R. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4604-11.2012 · Cited by 28
Williams, J. H., Wilcock, G. K., Seeburger, J., Dallob, A., Laterza, O., Potter, W., & Smith, A. D. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt64 · Cited by 26
Lim, B., Tsolaki, M., Soosaipillai, A., Brown, M., Zilakaki, M., Tagaraki, F., Fotiou, D., Koutsouraki, E., Grosi, E., Prassas, I., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0428 · Cited by 25
Rajkumar, A. P., Christensen, J. H., Mattheisen, M., Jacobsen, I., Bache, I., Pallesen, J., Grove, J., Qvist, P., McQuillin, A., Gurling, H. M., et al. (2015) · Bipolar Disorders · doi:10.1111/bdi.12239 · Cited by 24
Chen, B., & Bixby, J. L. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20391 · Cited by 24
Rat serum amyloid P component. Analysis of cDNA sequence and gene expression
Dowton, S. B., & Mcgrew, S. D. (1990) · Biochemical Journal · doi:10.1042/bj2700553 · Cited by 20
Rahim, M. A., & Hossain, M. A. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.006098 · Cited by 20
Dorsey, D. A., Mascó, D. H., Dikranian, K. T., Hyrc, K., Masciotra, L., Faddis, B. T., Soriano‐Navarro, M., Gru, A. A., Goldberg, M. P., & de Erausquin, G. A. (2006) · APOPTOSIS · doi:10.1007/s10495-006-5268-y · Cited by 11
Balke, D., Kuss, A. W., & Müller, S. (2015) · Life · doi:10.3390/life6010001 · Cited by 9
Cited by
Nilsson, J., Constantinescu, J., Nellgård, B., Jakobsson, P., Brum, W. S., Gobom, J., Forsgren, L., Dalla, K., Constantinescu, R., Zetterberg, H., et al. (2022) · Movement Disorders · doi:10.1002/mds.29287 · Cited by 64
Cheng, L., Chou, P.-Y., Hou, A.-T., Huang, C.-L., Shiu, W.-L., & Wang, S. (2022) · Food & Function · doi:10.1039/d2fo00165a · Cited by 61
Soldan, A., Oh, S., Ryu, T., Pettigrew, C. A., Zhu, Y., Moghekar, A., Xiao, M., Pontone, G. M., Albert, M., Na, C. H., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26725 · Cited by 51
Large‐scale deep proteomic analysis in Alzheimer's disease brain regions across race and ethnicity
Seifar, F., Fox, E. J., Shantaraman, A., Liu, Y., Dammer, E. B., Modeste, E., Duong, D. M., Yin, L., Trautwig, A. N., Guo, Q., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14360 · Cited by 52
Noone, D. P., Dijkstra, D. J., van der Klugt, T. T., van Veelen, P. A., de Ru, A. H., Hensbergen, P. J., Trouw, L. A., & Sharp, T. H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208144119 · Cited by 45
Metadata
- Authors
- Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M.
- Affiliations
- Universität Ulm (DE)
- Corresponding author
- Otto, Markus
- ORCID
- Venue
- Journal of Neural Transmission
- Published
- 2021-08-30
- Volume
- 129
- Issue
- 2
- Pages
- 207-230
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- PMC
- PMC8866268
- OpenAlex
- W3197743626
- Cited by
- 112
- References
- 181
- Citations by year
- 2026: 24 · 2025: 36 · 2024: 31 · 2023: 12 · 2022: 9
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Neural Transmission (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) (submittedVersion, other-oa)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Universität Ulm, Kommunikations- und Informationszentrum (kiz) (cc-by)
- Funders
- h2020 marie skłodowska-curie actions (860197)
- Universität Ulm
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- synaptic dysfunction, neurodegeneration, cerebrospinal fluid biomarkers, synaptic plasticity, cognitive impairment, neurodegenerative disease diagnosis
- MeSH terms
- Pentraxins, C-Reactive Protein, Nerve Tissue Proteins, Neuronal Plasticity, Synapses, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.